Creatine for Brain Health: Cognition, Sleep Loss, Mood & Safety — 2026 Review

Bottom line: Creatine clearly participates in brain energy metabolism, and human studies show that it can affect cognition under some conditions. But the case for a general-purpose nootropic effect is weaker than many summaries imply. A widely cited 2024 cognition meta-analysis reported benefits in selected domains, yet a 2026 methodological commentary identified double-counting of correlated outcomes that can inflate precision; EFSA had raised the same concern and concluded that a general cause-and-effect cognitive benefit was not established. A corrected memory meta-analysis likewise lost its overall significant effect, although a subgroup signal in older adults remained. The strongest recent stress-state experiment used a single very large research dose during prolonged sleep deprivation and should not be converted into a consumer protocol. Depression evidence remains very-low-certainty, and the newest kidney meta-analysis distinguishes misleading creatinine-based eGFR changes from measured GFR.

At a glance

---

What changed in the evidence picture

The important 2026 update is not simply “more positive studies.” It is better scrutiny of how the positive studies were pooled.

1. The 2024 cognition meta-analysis reported domain-specific benefits

Xu and colleagues pooled 16 randomized controlled trials involving 492 participants and reported favorable effects for memory, attention time, and processing-speed time, while overall cognition and executive function were not significantly improved. The authors rated memory evidence as moderate certainty and several other domains as low certainty. PMID 39070254

Taken at face value, that supports a selective rather than global cognitive effect.

2. A 2026 commentary identified a unit-of-analysis problem

A 2026 commentary examined the Xu meta-analysis and pointed out that several trials contributed multiple correlated cognitive outcomes from the same participants as if they were independent observations. That can artificially increase statistical precision and the chance of a positive pooled result. The commentary specifically noted repeated subtests from the same participant groups and recommended a re-analysis that accounts for dependence among outcomes. PMID 42039906

This is not a trivial technical footnote. It means the positive pooled estimates should be treated as provisional until re-analyzed appropriately.

3. EFSA reached a stricter conclusion from the human evidence

In 2024, the European Food Safety Authority assessed a proposed claim that daily creatine supplementation could improve cognitive function. EFSA concluded that a cause-and-effect relationship had not been established in the general adult population. The panel emphasized inconsistent effects across doses and studies, isolated positive endpoints among many null outcomes, weak mechanistic support for the specific claim, and concerns about how non-independent outcomes were pooled. PMID 39564533

The application was submitted by Alzchem Trostberg GmbH, a creatine manufacturer. That does not invalidate the evidence review; it is relevant context for why the claim was formally evaluated.

4. The memory story was also corrected after double-counting

The original 2023 memory meta-analysis reported an overall benefit. After a methodological criticism, the authors re-ran the analysis using composite effects so that the same participants were not counted repeatedly.

The corrected result was not statistically significant overall: SMD 0.19 (95% CI −0.07 to 0.46; P=0.15). A positive subgroup signal remained in older adults aged 66–76 years, while younger-adult results were null. Author reply, PMID 36644912

That makes the most defensible memory claim:

Creatine may improve memory in some older adults, but an overall memory benefit across healthy people is not established after correcting the meta-analysis for double-counting.

---

Cognition: plausible, selective, and not settled

Healthy, well-rested adults

The general healthy-adult literature is mixed. Some trials report improvements on individual tasks; others are null. Effects do not consistently generalize across memory, attention, processing speed, executive function, and global cognition.

That is why “creatine improves cognition” is too broad.

Older adults

Older adults remain one of the more interesting subgroups because the corrected memory analysis preserved a favorable signal there. But subgroup results are based on much smaller evidence sets than a broad population-wide claim, and they do not establish dementia prevention or treatment.

Vegetarians and vegans

People who consume little or no meat typically have lower dietary creatine exposure, making dietary pattern a plausible effect modifier. Some older studies found stronger cognitive responses in vegetarians, but the pattern is not consistent enough to predict who will respond.

“Possible effect modifier” is more accurate than “vegetarians need creatine for their brain.”

“Brain fog” and mental fatigue

“Brain fog” is not one standardized clinical outcome. It can arise from sleep loss, medication effects, anemia, thyroid disorders, mood disorders, infection, post-viral illness, nutritional deficiency, sleep apnea, and many other causes.

Creatine cannot be treated as a catch-all intervention for unexplained cognitive symptoms merely because brain energy metabolism is biologically relevant.

---

Sleep deprivation: unusually direct evidence, unusually specific conditions

A 2024 randomized crossover experiment studied participants during roughly 21 hours of sleep deprivation. Researchers administered a single 0.35 g/kg research dose of creatine monohydrate and used magnetic resonance spectroscopy alongside cognitive testing. They found changes in cerebral high-energy phosphate measures plus improvements on several cognitive-performance outcomes and processing speed versus placebo. PMID 38418482

This study is compelling because it links:

1. a defined metabolic stress state;
2. a creatine exposure;
3. direct brain-energy measurements;
4. and cognitive outcomes in the same experiment.

But its directness is also narrow:

• acute severe sleep deprivation;
• one unusually large research exposure;
• laboratory tasks;
• short follow-up;
• no evidence that repeated use of that exposure is appropriate;
• no proof of the same effect in ordinary, well-rested daily life.

Research dose ≠ recommendation.

The study reported institutional/public research funding through Forschungszentrum Jülich and RWTH Aachen rather than a creatine manufacturer. Scientific Reports study

---

Depression: a signal, not an established treatment

2025 meta-analysis

A 2025 systematic review and meta-analysis included 11 trials / 1,093 participants. The pooled standardized effect favored creatine, but certainty was rated very low. The estimated average change translated to about 2.2 points on the 17-item Hamilton Depression Rating Scale, below the authors’ prespecified minimal important difference of 3 points. Heterogeneity was substantial, and bias analyses suggested the apparent benefit may be overestimated. PMID 41189312

The authors explicitly noted that the true effect could be trivial or null.

2026 mental-disorders review

A 2026 systematic review of randomized trials found a small evidence base across mental disorders, with most studies focused on major depressive disorder and one bipolar-depression study. Some adjunctive trials were positive and others were not. Hypomania/mania events were reported in a very small bipolar evidence set, which is one reason this literature should not be reduced to a casual “mood supplement” claim. Sage review

The often-cited 2012 women-with-MDD trial

The 2012 randomized trial enrolled 52 women with major depressive disorder and tested creatine as an adjunct to escitalopram, not as stand-alone treatment. The creatine arm improved more rapidly and more strongly on HAM-D scores over eight weeks. The correct PubMed identifier is PMID 22864465. PMID 22864465

That study supports a defined adjunctive-treatment signal. It does not establish that:

• women in general benefit more than men;
• healthy people should use creatine for mood;
• creatine monotherapy treats major depression;
• creatine replaces antidepressants;
• or the trial regimen should be copied without clinical supervision.

Funding/conflict context matters here. The paper reports multiple public/nonprofit grants; it also discloses that senior authors had relationships with pharmaceutical companies and that one author was an inventor on related patent applications. PMC full text

---

Brain aging, dementia, and TBI: mechanism runs ahead of outcomes

The phosphocreatine system helps buffer cellular energy demand, so creatine has a strong mechanistic rationale in states of metabolic stress. Animal, spectroscopy, and disease-model work has explored neurodegeneration, ischemia, mitochondrial stress, and traumatic brain injury.

Those data support biological plausibility.

They do not establish that routine supplementation:

• prevents Alzheimer’s disease;
• prevents Parkinson’s disease;
• prevents concussion;
• lowers long-term dementia risk;
• reliably improves recovery after TBI;
• or should be used prophylactically for contact-sport brain protection.

The evidence label here is research interest, not preventive efficacy.

---

Brain creatine is not simply “muscle creatine in the skull”

The brain synthesizes creatine locally and tightly regulates transport across the blood-brain barrier. Supplementation can alter brain creatine-related measures, but the response is smaller and less predictable than the increase typically measured in skeletal muscle.

That is why borrowing a sports-loading protocol and calling it a “brain protocol” is not evidence-based.

The sleep-deprivation experiment suggests that high metabolic demand may alter central creatine handling or utilization, but one stress-state laboratory result does not establish a routine nootropic strategy.

---

Why this page does not give a “brain-health dose”

The literature uses heterogeneous regimens for different questions:

• short loading-style studies;
• multi-week daily supplementation;
• acute high-exposure stress experiments;
• psychiatric adjunctive trials;
• athletic protocols;
• disease-specific trials.

There is no single regimen validated across memory, depression, sleep deprivation, healthy aging, and mental fatigue.

The previous version of this page offered fixed daily dosing, loading, and onset guidance. Those recommendations were removed because they exceeded what the brain-outcome literature can establish.

A study exposure tells you how an experiment was conducted. It does not automatically become a personal-use instruction.

---

Kidney safety: the newest meta-analysis separates measured from creatinine-based GFR

A July 2026 systematic review/meta-analysis included 26 randomized trials and 1,036 participants. Creatine increased serum creatinine and produced an apparent reduction in GFR when GFR was estimated using creatinine-based methods. However, no significant change was seen when GFR was assessed using Cr-EDTA, an exogenous filtration marker, and no significant overall changes were found in proteinuria or albuminuria. 2026 kidney meta-analysis

That distinction is crucial: because creatinine is a breakdown product related to creatine metabolism, supplementation can make serum-creatinine-based kidney estimates look worse without demonstrating a true fall in filtration.

What the current pooled evidence supports

• Serum creatinine can rise with creatine supplementation.
• Creatinine-based eGFR can therefore fall artifactually.
• The newest pooled analysis did not find a significant Cr-EDTA-measured GFR reduction.
• Proteinuria and albuminuria did not show convincing pooled injury signals.

What remains uncertain

• Cystatin C was available in only a small number of trials.
• Evidence in non-dialysis CKD stages 1–5 is notably sparse/absent in the newest review.
• Hemodialysis trials were small.
• Many studies remain short to medium duration, even though some longer studies exist.
• Product purity and co-use of other substances can alter real-world risk.

The 2026 review reported CAPES support for its article-processing charge and declared no competing interests. Springer funding/conflict statement

This is more precise than either “creatine damages kidneys” or “creatine can never affect kidney tests.”

---

Product and formulation boundary

The cognitive literature overwhelmingly concerns creatine monohydrate.

It does not establish superior brain effects for:

• creatine hydrochloride;
• buffered creatine;
• creatine nitrate;
• gummies;
• proprietary nootropic blends;
• or branded products merely because they contain creatine.

Evidence transfers most directly when the chemical form, exposure, population, and outcome actually resemble the study being cited.

---

Funding, conflicts, and evidence concentration audit

A recurring problem in supplement evidence is evidence concentration: a small number of trials or research groups can dominate a meta-analysis, and multiple outcomes from the same participants can create the illusion of a larger evidence base. The creatine-cognition literature is a concrete example of why raw citation count is not the same as independent replication.

---

Evidence ledger

---

FAQs

Does creatine improve memory?

Not reliably across everyone. The corrected memory meta-analysis was not significant overall, although a positive subgroup signal remained in older adults. That is encouraging but not equivalent to a universal memory benefit. PMID 36644912

Does creatine work as a nootropic?

It can affect cognition in some experimental contexts, especially metabolic stress such as prolonged sleep deprivation, but a broad nootropic effect in healthy well-rested adults is not established. EFSA reached the same general conclusion when evaluating a formal cognitive health claim. PMID 39564533

Does creatine help depression?

Possibly as an adjunct in some settings, but certainty is very low. The 2025 meta-analysis found an average effect below its prespecified minimal important difference and warned that the true effect may be trivial or null. It should not be framed as a replacement for established depression treatment. PMID 41189312

Does creatine hurt the kidneys?

Current randomized evidence does not show a convincing measured-GFR injury signal in studied adults. Creatine can raise serum creatinine and make creatinine-based eGFR appear lower, which is not the same thing as proven kidney damage. Evidence remains incomplete in some CKD populations. 2026 kidney meta-analysis

What is the best creatine dose for brain health?

There is no single validated brain-health dose across cognition, sleep deprivation, mood, and aging outcomes. High research exposures used in acute experiments should not be converted into DIY protocols.

---

Final verdict

Creatine has a strong biological rationale in brain energy metabolism and a legitimate human neuroscience literature. But the strongest 2026 interpretation is more conservative than the supplement-market version:

• broad cognitive enhancement in healthy adults is not established;
• the most cited recent cognition meta-analysis has a double-counting problem that can inflate precision;
• a corrected memory analysis is null overall, with a remaining older-adult subgroup signal;
• acute sleep-deprivation evidence is unusually direct but highly specific;
• depression results are promising but very-low-certainty and below a clinical-importance threshold on average;
• kidney safety looks reassuring in measured-GFR analyses, while creatinine-based estimates can be misleading;
• and there is no defensible universal “brain dose.”

Evidence grade: mixed human evidence — strongest for specific stress-state physiology and selected subgroup signals, weaker for a general-purpose nootropic claim.

References

1. Xu et al. 2024 cognition systematic review/meta-analysis — PMID 39070254
2. Citherlet 2026 commentary on double-counting — PMID 42039906
3. EFSA 2024 creatine/cognition health-claim evaluation — PMID 39564533
4. Prokopidis et al. 2023 corrected memory meta-analysis reply — PMID 36644912
5. Gordji-Nejad et al. 2024 sleep-deprivation crossover — PMID 38418482
6. Eckert et al. 2025 depression meta-analysis — PMID 41189312
7. Fares et al. 2026 systematic review of creatine in mental disorders
8. Lyoo et al. 2012 adjunctive creatine + SSRI trial — PMID 22864465
9. de Souza Almeida et al. 2026 kidney-health systematic review/meta-analysis
10. Naeini et al. 2025 kidney-function systematic review/meta-analysis

Related Articles

• Lion's Mane: Cognition, Mood, Dose & Evidence
• Magnesium Glycinate: Sleep Evidence & Safety
• Supplement Safety Checklist